Applicable 0 10 0 10 O
to 11 13 11 13 O
Cohorts 14 21 14 21 O
1 22 23 22 23 O
- 23 24 23 24 O
4 24 25 24 25 O
and 26 29 26 29 O
Cohort 30 36 30 36 O
6 37 38 37 38 O
only 39 43 39 43 O
: 43 44 43 44 O
Previous 45 53 45 53 B-treatment
anti 54 58 54 58 I-treatment
- 58 59 58 59 I-treatment
cancer 59 65 59 65 I-treatment
and 66 69 66 69 O
investigational 70 85 70 85 B-treatment
agents 86 92 86 92 I-treatment
within 93 99 93 99 O
4 100 101 100 101 B-upper_bound
weeks 102 107 102 107 I-upper_bound
or 108 110 108 110 O
≤ 111 112 111 112 O
5 113 114 113 114 B-upper_bound
x 115 116 115 116 O
half 117 121 117 121 O
- 121 122 121 122 O
life 122 126 122 126 O
of 127 129 127 129 O
the 130 133 130 133 O
agent 134 139 134 139 O
( 140 141 140 141 O
whichever 141 150 141 150 O
is 151 153 151 153 O
longer 154 160 154 160 O
) 160 161 160 161 O
before 162 168 162 168 O
first 169 174 169 174 O
dose 175 179 175 179 O

At 0 2 180 182 O
least 3 8 183 188 O
one 9 12 189 192 B-lower_bound
measurable 13 23 193 203 O
lesion 24 30 204 210 O
as 31 33 211 213 O
defined 34 41 214 221 O
by 42 44 222 224 O
RECIST 45 51 225 231 O
1.1 52 55 232 235 O

Clinically 0 10 236 246 O
significant 11 22 247 258 O
, 22 23 258 259 O
uncontrolled 24 36 260 272 O
heart 37 42 273 278 B-chronic_disease
diseases 43 51 279 287 I-chronic_disease

Cohort 0 6 288 294 O
1 7 8 295 296 O
: 8 9 296 297 O
Pre 10 13 298 301 O
- 13 14 301 302 O
treated 14 21 302 309 O
patients 22 30 310 318 O
with 31 35 319 323 O
cMET 36 40 324 328 B-clinical_variable
GCN 41 44 329 332 I-clinical_variable
≥ 45 46 333 334 O
6 47 48 335 336 B-lower_bound

Cohort 0 6 337 343 O
2 7 8 344 345 O
: 8 9 345 346 O
Pre 10 13 347 350 O
- 13 14 350 351 O
treated 14 21 351 358 O
patients 22 30 359 367 O
with 31 35 368 372 O
cMET 36 40 373 377 B-clinical_variable
GCN 41 44 378 381 I-clinical_variable
≥4 45 47 382 384 O
and 48 51 385 388 O
< 52 53 389 390 O
6 54 55 391 392 B-upper_bound

Cohort 0 6 393 399 O
3 7 8 400 401 O
: 8 9 401 402 O
Pre 10 13 403 406 O
- 13 14 406 407 O
treated 14 21 407 414 O
patients 22 30 415 423 O
with 31 35 424 428 O
cMET 36 40 429 433 B-clinical_variable
GCN 41 44 434 437 I-clinical_variable
< 45 46 438 439 O
4 47 48 440 441 B-upper_bound

Cohort 0 6 442 448 O
5 7 8 449 450 O
: 8 9 450 451 O
Treatment 10 19 452 461 B-treatment
- 19 20 461 462 O
naïve 20 25 462 467 O
patients 26 34 468 476 O
with 35 39 477 481 O
cMET 40 44 482 486 O
dysregulation 45 58 487 500 O

Cohort 0 6 501 507 O
6 7 8 508 509 O
: 8 9 509 510 O
Pre 10 13 511 514 O
- 13 14 514 515 O
treated 14 21 515 522 O
patients 22 30 523 531 O
with 31 35 532 536 O
either 36 42 537 543 O
cMET 43 47 544 548 B-clinical_variable
GCN 48 51 549 552 I-clinical_variable
≥ 52 53 553 554 O
10 54 56 555 557 B-lower_bound
without 57 64 558 565 O
cMET 65 69 566 570 B-treatment
mutations 70 79 571 580 I-treatment
or 80 82 581 583 I-treatment
cMET 83 87 584 588 I-treatment
mutations 88 97 589 598 I-treatment
regardless 98 108 599 609 O
of 109 111 610 612 O
cMET 112 116 613 617 O
GCN 117 120 618 621 O

Cohort 0 6 622 628 O
7 7 8 629 630 O
: 8 9 630 631 O
Treatment 10 19 632 641 B-treatment
- 19 20 641 642 O
naïve 20 25 642 647 O
patients 26 34 648 656 O
with 35 39 657 661 O
cMET 40 44 662 666 B-treatment
mutations 45 54 667 676 I-treatment
regardless 55 65 677 687 O
of 66 68 688 690 O
cMET 69 73 691 695 O
GCN 74 77 696 699 O

ECOG 0 4 700 704 B-clinical_variable
performance 5 16 705 716 I-clinical_variable
status 17 23 717 723 I-clinical_variable
( 24 25 724 725 I-clinical_variable
PS 25 27 725 727 I-clinical_variable
) 27 28 727 728 I-clinical_variable
of 29 31 729 731 O
0 32 33 732 733 B-lower_bound
or 34 36 734 736 O
1 37 38 737 738 B-upper_bound
Details 39 46 739 746 O
and 47 50 747 750 O
other 51 56 751 756 O
protocol 57 65 757 765 O

EGFR 0 4 766 770 B-clinical_variable
wt 5 7 771 773 O
as 8 10 774 776 O
per 11 14 777 780 O
patient 15 22 781 788 O
standard 23 31 789 797 O
of 32 34 798 800 O
care 35 39 801 805 O
by 40 42 806 808 O
a 43 44 809 810 O
validated 45 54 811 820 O
test 55 59 821 825 O

Histologically 0 14 826 840 O
or 15 17 841 843 O
cytologically 18 31 844 857 O
confirmed 32 41 858 867 O
diagnosis 42 51 868 877 O
of 52 54 878 880 O
NSCLC 55 60 881 886 B-cancer

Impairment 0 10 887 897 B-chronic_disease
of 11 13 898 900 I-chronic_disease
GI 14 16 901 903 I-chronic_disease
function 17 25 904 912 I-chronic_disease
or 26 28 913 915 I-chronic_disease
GI 29 31 916 918 I-chronic_disease
disease 32 39 919 926 I-chronic_disease
that 40 44 927 931 O
may 45 48 932 935 O
significantly 49 62 936 949 O
alter 63 68 950 955 O
the 69 72 956 959 O
absorption 73 83 960 970 O
of 84 86 971 973 O
INC280 87 93 974 980 B-treatment

Patients 0 8 981 989 O
must 9 13 990 994 O
have 14 18 995 999 O
recovered 19 28 1000 1009 O
from 29 33 1010 1014 O
all 34 37 1015 1018 O
toxicities 38 48 1019 1029 O
related 49 56 1030 1037 O
to 57 59 1038 1040 O
prior 60 65 1041 1046 B-treatment
anticancer 66 76 1047 1057 I-treatment
therapies 77 86 1058 1067 I-treatment
to 87 89 1068 1070 O
grade 90 95 1071 1076 O
≤ 96 97 1077 1078 O
1 98 99 1079 1080 B-upper_bound
( 100 101 1081 1082 O
CTCAE 101 106 1082 1087 B-clinical_variable
v 107 108 1088 1089 O
4.03 109 113 1090 1094 O
) 113 114 1094 1095 O

Patients 0 8 1096 1104 O
receiving 9 18 1105 1114 O
treatment 19 28 1115 1124 B-treatment
with 29 33 1125 1129 I-treatment
any 34 37 1130 1133 I-treatment
enzyme 38 44 1134 1140 I-treatment
- 44 45 1140 1141 I-treatment
inducing 45 53 1141 1149 I-treatment
anticonvulsant 54 68 1150 1164 I-treatment

Patients 0 8 1165 1173 O
receiving 9 18 1174 1183 O
treatment 19 28 1184 1193 B-treatment
with 29 33 1194 1198 I-treatment
medications 34 45 1199 1210 I-treatment
that 46 50 1211 1215 O
can 51 54 1216 1219 O
not 54 57 1219 1222 O
be 58 60 1223 1225 O
discontinued 61 73 1226 1238 O
at 74 76 1239 1241 O
least 77 82 1242 1247 O
1 83 84 1248 1249 B-lower_bound
week 85 89 1250 1254 I-lower_bound
prior 90 95 1255 1260 I-lower_bound
to 96 98 1261 1263 O
first 99 104 1264 1269 B-treatment
INC280 105 111 1270 1276 I-treatment
treatment 112 121 1277 1286 I-treatment
and 122 125 1287 1290 O
for 126 129 1291 1294 O
the 130 133 1295 1298 O
duration 134 142 1299 1307 O
of 143 145 1308 1310 O
the 146 149 1311 1314 O
study 150 155 1315 1320 O

Patients 0 8 1321 1329 O
with 9 13 1330 1334 O
any 14 17 1335 1338 O
grade 18 23 1339 1344 O
of 24 26 1345 1347 O
alopecia 27 35 1348 1356 B-chronic_disease

Patients 0 8 1357 1365 O
with 9 13 1366 1370 O
characterized 14 27 1371 1384 O
ALK 28 31 1385 1388 B-cancer
- 31 32 1388 1389 O
positive 32 40 1389 1397 O
rearrangement 41 54 1398 1411 O

Patients 0 8 1412 1420 O
with 9 13 1421 1425 O
characterized 14 27 1426 1439 O
EGFR 28 32 1440 1444 B-clinical_variable
mutations 33 42 1445 1454 O
that 43 47 1455 1459 O
predict 48 55 1460 1467 O
sensitivity 56 67 1468 1479 O
to 68 70 1480 1482 O
EGFR 71 75 1483 1487 B-treatment
therapy 76 83 1488 1495 I-treatment
, 83 84 1495 1496 O
including 85 94 1497 1506 O
, 94 95 1506 1507 O
but 96 99 1508 1511 O
not 100 103 1512 1515 O
limited 104 111 1516 1523 O
to 112 114 1524 1526 O
exon 115 119 1527 1531 O
19 120 122 1532 1534 O
deletions 123 132 1535 1544 O
and 133 136 1545 1548 O
exon 137 141 1549 1553 O
21 142 144 1554 1556 O
mutations 145 154 1557 1566 O

Pregnant 0 8 1567 1575 B-pregnancy

Presence 0 8 1576 1584 O
or 9 11 1585 1587 O
history 12 19 1588 1595 O
of 20 22 1596 1598 O
interstitial 23 35 1599 1611 B-chronic_disease
lung 36 40 1612 1616 I-chronic_disease
disease 41 48 1617 1624 I-chronic_disease
or 49 51 1625 1627 O
interstitial 52 64 1628 1640 B-chronic_disease
pneumonitis 65 76 1641 1652 I-chronic_disease
, 76 77 1652 1653 O
including 78 87 1654 1663 O
clinically 88 98 1664 1674 O
significant 99 110 1675 1686 O
radiation 111 120 1687 1696 B-treatment
pneumonitis 121 132 1697 1708 I-treatment

Prior 0 5 1709 1714 O
treatment 6 15 1715 1724 B-treatment
with 16 20 1725 1729 I-treatment
crizotinib 21 31 1730 1740 I-treatment
, 31 32 1740 1741 O
or 33 35 1742 1744 O
any 36 39 1745 1748 O
other 40 45 1749 1754 O
cMET 46 50 1755 1759 B-treatment
or 51 53 1760 1762 O
HGF 54 57 1763 1766 B-treatment
inhibitor 58 67 1767 1776 I-treatment

Sexually 0 8 1777 1785 O
active 9 15 1786 1792 O
males 16 21 1793 1798 B-gender
unless 22 28 1799 1805 O
they 29 33 1806 1810 O
use 34 37 1811 1814 B-contraception_consent
a 38 39 1815 1816 I-contraception_consent
condom 40 46 1817 1823 I-contraception_consent
during 47 53 1824 1830 I-contraception_consent
intercourse 54 65 1831 1842 I-contraception_consent

Stage 0 5 1843 1848 B-lower_bound
IIIB 6 10 1849 1853 I-lower_bound
or 11 13 1854 1856 O
IV 14 16 1857 1859 B-upper_bound
NSCLC 17 22 1860 1865 B-cancer
( 23 24 1866 1867 O
any 24 27 1867 1870 O
histology 28 37 1871 1880 O
) 37 38 1880 1881 O
at 39 41 1882 1884 O
the 42 45 1885 1888 O
time 46 50 1889 1893 O
of 51 53 1894 1896 O
study 54 59 1897 1902 O
entry 60 65 1903 1908 O

Strong 0 6 1909 1915 B-treatment
inducers 7 15 1916 1924 I-treatment
of 16 18 1925 1927 I-treatment
CYP3A4 19 25 1928 1934 I-treatment

To 0 2 1935 1937 O
be 3 5 1938 1940 O
eligible 6 14 1941 1949 O
for 15 18 1950 1953 O
Cohort 19 25 1954 1960 O
5 26 27 1961 1962 O
and 28 31 1963 1966 O
Cohort 32 38 1967 1973 O
7 39 40 1974 1975 O
, 40 41 1975 1976 O
patients 42 50 1977 1985 O
must 51 55 1986 1990 O
not 56 59 1991 1994 O
have 60 64 1995 1999 O
received 65 73 2000 2008 O
any 74 77 2009 2012 O
systemic 78 86 2013 2021 B-treatment
therapy 87 94 2022 2029 I-treatment
for 95 98 2030 2033 O
advanced 99 107 2034 2042 O
/ 107 108 2042 2043 O
metastatic 108 118 2043 2053 B-cancer
disease 119 126 2054 2061 O

To 0 2 2062 2064 O
be 3 5 2065 2067 O
eligible 6 14 2068 2076 O
for 15 18 2077 2080 O
Cohort 19 25 2081 2087 O
6 26 27 2088 2089 O
, 27 28 2089 2090 O
patients 29 37 2091 2099 O
must 38 42 2100 2104 O
have 43 47 2105 2109 O
failed 48 54 2110 2116 O
one 55 58 2117 2120 O
prior 59 64 2121 2126 B-treatment
line 65 69 2127 2131 I-treatment
of 70 72 2132 2134 I-treatment
systemic 73 81 2135 2143 I-treatment
therapy 82 89 2144 2151 I-treatment
for 90 93 2152 2155 O
advanced 94 102 2156 2164 O
/ 102 103 2164 2165 O
metastatic 103 113 2165 2175 B-cancer
disease 114 121 2176 2183 I-cancer

To 0 2 2184 2186 O
be 3 5 2187 2189 O
eligible 6 14 2190 2198 O
for 15 18 2199 2202 O
Cohorts 19 26 2203 2210 O
1 27 28 2211 2212 O
- 28 29 2212 2213 O
4 29 30 2213 2214 O
, 30 31 2214 2215 O
patients 32 40 2216 2224 O
must 41 45 2225 2229 O
have 46 50 2230 2234 O
failed 51 57 2235 2241 O
one 58 61 2242 2245 O
or 62 64 2246 2248 O
two 65 68 2249 2252 O
prior 69 74 2253 2258 O
lines 75 80 2259 2264 O
of 81 83 2265 2267 O
systemic 84 92 2268 2276 B-treatment
therapy 93 100 2277 2284 I-treatment
for 101 104 2285 2288 O
advanced 105 113 2289 2297 O
/ 113 114 2297 2298 O
metastatic 114 124 2298 2308 B-cancer
disease 125 132 2309 2316 I-cancer

Women 0 5 2317 2322 B-gender
of 6 8 2323 2325 O
child 9 14 2326 2331 O
- 14 15 2331 2332 O
bearing 15 22 2332 2339 O
potential 23 32 2340 2349 O

nursing 0 7 2350 2357 O
women 8 13 2358 2363 B-gender

